Artiva Biotherapeutics (ARTV) Proxy filing summary

Executive summary

• Annual Meeting scheduled for September 8, 2026, to be held virtually for all stockholders of record as of July 20, 2026.

• Three main proposals: election of two Class II directors, ratification of KPMG LLP as auditor, and approval of amendments to the 2024 Equity Incentive Plan.

• Proxy materials and annual report are available online; voting can be done via internet, phone, mail, or during the meeting.

Voting matters and shareholder proposals

• Proposal 1: Elect Brian Daniels, M.D., and Laura Stoppel, Ph.D., as Class II directors until 2029.

• Proposal 2: Ratify KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Proposal 3: Approve amendment to 2024 Equity Incentive Plan, increasing share reserve by 5,097,095 shares and including pre-funded warrants in the annual increase calculation.

• Shareholders may submit proposals for the 2027 Annual Meeting by specified deadlines and procedures.

Board of directors and corporate governance

• Board consists of seven members, divided into three classes with staggered terms.

• Majority of directors are independent per Nasdaq standards; board diversity and independence are regularly reviewed.

• Board leadership is separated, with an independent non-executive Chair distinct from the CEO.

• Seven standing committees: Audit, Compensation, Nominating and Corporate Governance, Clinical Development, Commercial Planning, Philanthropic, and Technical Operations.

• Board and committees met regularly in 2025, with high attendance.